mydrugindex
Kenyan Reference & Directory
Free lookups today: 0/3 · Unlimited with Pro Subscribe from KES 99
Free lookups: 0/3 Unlimited with Pro → Browse by class Interactions · Tip: type at least 2 letters, then pick a result

INN monograph

Quinine

Antimalarial · POM

POM

Verified · Updated 01 Aug 2026 · Source: Local active-ingredient clinical extract; FDA drug label via OpenFDA/DailyMed; RxNorm (NLM RxNav); PubChem

Class
Antimalarial
Schedule
POM
Route
ORAL / PARENTERAL (severe malaria)
Onset
Hours (artemisinins rapid parasite clearance)
Duration
Regimen-dependent (ACT 3 days typical)
Pregnancy
Treat malaria — untreate...
Renal
Supportive care critical...
High-alert
No

Kenya market

Wholesale / list prices where loaded

From
Median
Brands
13

Risk first

Contraindications

  • Known hypersensitivity.
  • Agent-specific: e.g. mefloquine in active depression/psychosis/seizure disorder
  • primaquine in G6PD deficiency (haemolysis).
  • Always check agent-specific absolute contraindications.

Precautions

  • Confirm species and severity.
  • ECG risk with some agents (quinine, piperaquine).
  • Pregnancy: follow Kenya/WHO trimester-specific ACT guidance.
  • Vomiting within 30–60 min may need redosing per protocol.

Point of care

Dosing

Adult

Orally 600mg [of stat] TID x I/52. I.V. infusion: Loading dose: 20mg/kg [max. 1.4g] over hours, then 10mg/kg [max. 700mg] after every 8 hours over 4 hours. When the patient can swallow the dose switch to artemisinin combined therapy. [ACT]

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Supportive care critical in severe malaria; adjust supportive drugs as needed.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.

Hepatic

Monitor if pre-existing liver disease; many agents hepatically metabolised.

Safety

Drug interactions

Open checker →
  • Kenya: follow current MoH malaria guidelines for uncomplicated vs severe disease.
  • Test before treat when feasible.
  • Complete full ACT course.
  • Severe malaria is an emergency — parenteral artesunate, not oral therapy alone.

Safety

Adverse effects

  • Visual disturbances, CVS disturbances, blood dyscrasias, GI disturbances, abortion after excessive dosages, cardiac function disturbances, cinchonism, skin rashes, angioedema, asthma precipitation.

Use

Indications

  • Acute attacks of P. falciparum resistant to common antimalarials.
  • Clinical selection for Quinine should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Antimalarial.
  • Confirm site-specific dose, duration and monitoring before prescribing.

Pharmacology

Mode of action

Thought to inhibit heme polymerase activity resulting in the accumulation of free heme, which is toxic to the parasites.

Thought to inhibit heme polymerase activit… Artemisinins generate carbon-centred free… Partner drugs (lumefantrine, piperaquine,…
Full mechanism text

Thought to inhibit heme polymerase activity resulting in the accumulation of free heme, which is toxic to the parasites. Artemisinins generate carbon-centred free radicals after activation by parasite haem-iron, damaging parasite proteins and membranes — rapid blood schizonticidal effect. Partner drugs (lumefantrine, piperaquine, etc.) provide longer-acting clearance of residual parasites. Other classes act on haem detoxification, electron transport, or folate pathways depending on agent.

ADME

Pharmacokinetics & PD

Onset Hours (artemisinins rapid parasite clearance)
Duration Regimen-dependent (ACT 3 days typical)
Route ORAL / PARENTERAL (severe malaria)
Absorption enhanced by fat-containing food. Complex
Metabolism (CYP3A4) for several partners. Severe malaria: parenteral artesunate preferred first-line in most guidelines.

Kenya

Brands & prices

13 listed
Brand Company Pack KES
Curaquine Regal Pharmaceuticals Standard Commercial Pack
Mosqin Indus Pharma Standard Commercial Pack
Quinalin Shelys Pharmaceuticals Ltd. Standard Commercial Pack
Quinamor Sphinx Pharmaceuticals Ltd Standard Commercial Pack
Quinax Troikaa Pharmaceuticals Standard Commercial Pack
Quinidil Biodeal Laboratories Ltd. Standard Commercial Pack
Quinine Independent / Registered Supplier Standard Commercial Pack
Quinine, by Allied Laboratory & Allied Ltd. Standard Commercial Pack
Quinine, by Laborate Laborate Standard Commercial Pack
Quinine, by Medisel Distributed by Medisel (K) Limited Standard Commercial Pack
Quinine-Universal Universal Corporation Ltd. Standard Commercial Pack
Quinine Mixture Laboratory & Allied Ltd. Standard Commercial Pack
Topquine Dawa Limited Standard Commercial Pack

Special populations

Pregnancy & lactation

Pregnancy

Treat malaria — untreated infection risks mother and fetus. Use trimester-appropriate regimens per Kenya MoH / WHO.

Lactation

Most first-line ACTs compatible; continue breastfeeding with maternal treatment.

Diet

Food & alcohol

  • Food
  • Food

Trust

Sources & disclaimer

Source: Local active-ingredient clinical extract; FDA drug label via OpenFDA/DailyMed; RxNorm (NLM RxNav); PubChem

Open source link

Last reviewed: 01 Aug 2026

Decision support only — not a substitute for clinical judgment, product SmPC, or Kenya STG/EML.

Kenya Verified Health Registry